Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$169.67B | 19.9x | -1.3 | HK$58.55 | 7.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4% Upside | Upgrade to Pro+ | |
Hansoh Pharmaceutical Group | Hong Kong | Healthcare | Pharmaceuticals | HK$110.02B | 25.7x | 0.29 | HK$18.76 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.9% Upside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$71.17B | 22.9x | -0.69 | HK$18.56 | 7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.9% Downside | Upgrade to Pro+ | |
Sinopharm Group Co | Hong Kong | Healthcare | Pharmaceuticals | HK$64.13B | 6.9x | -2.23 | HK$20.55 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.4% Upside | Upgrade to Pro+ | |
Innovent Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$63.14B | -45.1x | -4.15 | HK$38.55 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.7% Upside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$61.13B | 59.8x | -0.96 | HK$34.80 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.2% Upside | Upgrade to Pro+ | |
Sino Biopharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$58.80B | 13.6x | 0.2 | HK$3.23 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.7% Upside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$58.52B | -74.9x | 0.54 | HK$65.60 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.8% Upside | Upgrade to Pro+ | |
CSPC Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$58.13B | 10.7x | -0.69 | HK$5.01 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.7% Upside | Upgrade to Pro+ | |
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$56.23B | 27.9x | 1.19 | HK$14.92 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.7% Upside | Upgrade to Pro+ | |
Shanghai Pharma Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$47.79B | 11.2x | -1.54 | HK$12.88 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.2% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$41.05B | -188x | -3.02 | HK$189.80 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.1% Upside | Upgrade to Pro+ | |
Shanghai Fosun Pharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$37.66B | 16.9x | -0.72 | HK$14.16 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.8% Upside | Upgrade to Pro+ | |
WuXi XDC Cayman | Hong Kong | Healthcare | Pharmaceuticals | HK$34.45B | 48.1x | 0.46 | HK$31 | 7.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2% Upside | Upgrade to Pro+ | |
China Resources Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$33.49B | 8.3x | 0.82 | HK$5.33 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.2% Upside | Upgrade to Pro+ | |
Asymchem Laboratories Tianjin | Hong Kong | Healthcare | Pharmaceuticals | HK$32.74B | 39.9x | -0.53 | HK$55.10 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.9% Upside | Upgrade to Pro+ | |
Guangzhou Baiyunshan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$29.49B | 8x | -0.64 | HK$18.12 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.7% Upside | Upgrade to Pro+ | |
Livzon Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$24.62B | 17.3x | 8.27 | HK$27 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.5% Upside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$24.20B | -17.4x | -3.72 | HK$11.34 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HUTCHMED | Hong Kong | Healthcare | Pharmaceuticals | HK$23.64B | -70.4x | 8.16 | HK$26.20 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.9% Upside | Upgrade to Pro+ | |
Shandong Weigao Medical Polymer | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$21.89B | 10.5x | -0.51 | HK$4.79 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.5% Upside | Upgrade to Pro+ | |
Zai Lab | Hong Kong | Healthcare | Pharmaceuticals | HK$21.42B | -9.7x | -0.92 | HK$21.95 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
United Laboratories Int | Hong Kong | Healthcare | Pharmaceuticals | HK$20.97B | 6.8x | 0.22 | HK$11.54 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.8% Upside | Upgrade to Pro+ | |
China Medical System | Hong Kong | Healthcare | Pharmaceuticals | HK$18.56B | 12.6x | -0.22 | HK$7.71 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29% Upside | Upgrade to Pro+ | |
Shenzhen Hepalink | Hong Kong | Healthcare | Pharmaceuticals | HK$18.22B | -116.1x | 0.64 | HK$4.04 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.7% Downside | Upgrade to Pro+ | |
Simcere | Hong Kong | Healthcare | Pharmaceuticals | HK$17.62B | -14.4x | 0.11 | HK$7.20 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.3% Upside | Upgrade to Pro+ | |
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$17.18B | -5.5x | 0.61 | HK$17.18 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.3% Upside | Upgrade to Pro+ | |
XtalPi Holdings | Hong Kong | Healthcare | Healthcare Equipment & Supplies | HK$16.97B | -2.6x | HK$4.57 | -8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
China Grand Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$16.28B | 6.8x | 3.49 | HK$4.65 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.1% Upside | Upgrade to Pro+ | |
3SBio | Hong Kong | Healthcare | Pharmaceuticals | HK$14.67B | 8.6x | -0.78 | HK$6.22 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27% Upside | Upgrade to Pro+ |